Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bretten – page 73

1 040 clinical trials in Bretten, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bretten at a glance
1 040
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 040 trials in Bretten

Open in trial search

Neoplasm malignant+2

Not recruiting

Study on the Effects of Selpercatinib in Children with Advanced RET-Altered Solid Tumors or Primary Central Nervous System Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Selpercatinib
  • Sponsor:Loxo Oncology Inc.

Study on Long-term Safety of Seralutinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Study Comparing Lorlatinib and Crizotinib for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Lorlatinib
  • Sponsor:Pfizer Inc.

Study of Nivolumab and Relatlimab for Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Universitaetsklinikum Essen AöR

Study on the Long-term Safety and Efficacy of Ralinepag for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Study Comparing Datopotamab Deruxtecan to Chemotherapy in Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Study of Entrectinib in Children and Adolescents with Advanced or Metastatic Solid Tumors or Primary CNS Tumors with No Satisfactory Treatment Options

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Entrectinib
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG

Neoplasm malignant

Not recruiting

Study on the Safety and Anti-tumor Effects of GEN1042 Alone or with Pembrolizumab and Chemotherapy in Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Genmab A/S

Study on Treprostinil Palmitil Inhalation Powder for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Primary amyloidosis

Not recruiting

Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study on the Safety of Osimertinib with Radiation for Patients with Stage IV EGFR-Mutation Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AIO-Studien gGmbH

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bretten

What the registry says about research in the country

01 Infectious Disease Prevention

Ongoing clinical trials focusing on meningococcal infection prevention through vaccination studies. Research is evaluating the long-term effectiveness of a quadrivalent conjugate vaccine in providing protection against multiple bacterial strains.

  • Vaccine Immunogenicity
  • Long-term Protection
  • Pediatric Vaccination

Studies involve children and adolescents across multiple European centers, examining immune responses and safety profiles of booster vaccinations administered at 5- and 10-year intervals.

02 Pediatric Immunology

Research centered on understanding the persistence of immunity in young populations. The booster vaccination studies are specifically designed to evaluate immune system responses in previously vaccinated children.

  • Immune Response Duration
  • Booster Effectiveness
  • Safety Assessment

These trials are being conducted across multiple sites in Finland, Germany, Spain, and Hungary, focusing on protective immunity development in pediatric populations.

03 Preventive Medicine

Investigation of preventive strategies against multiple meningococcal serogroups through advanced vaccine technology. The research aims to establish optimal timing for booster doses.

  • Multi-strain Protection
  • Vaccination Schedule Optimization
  • Population Health Impact

The study evaluates the effectiveness of vaccination strategies in providing comprehensive protection against various meningococcal strains.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.